Imugene Limited (ASX: $IMU) Patent Grant Announcement

Imugene Limited (ASX: $IMU) has received a Notice of Grant from the Chinese Patent Office for its oncolytic virotherapy CF33, including VAXINIA and CHECKvacc. The granted claims protect its oncolytic virotherapy CF33, providing method of composition and method of use protection to 2037.

Imugene MD & CEO Leslie Chong's Statement

Imugene MD & CEO Leslie Chong said, 'Imugene receiving these patent grants for the CF33 family of oncolytic viruses is a crucial step forward and with China, Japan, and South Korea being the largest healthcare markets in Asia, this is a particularly important patent milestone.'

Summary of Imugene's CF33 Patent Grant

Imugene Limited (ASX: $IMU) has achieved a significant milestone with the grant of CF33 patent in China, adding to earlier grants in Japan and South Korea. The patent titled 'CHIMERIC POXVIRUS COMPOSITION AND USES THEREOF' protects the method of composition and method of use of Imugene's licensed oncolytic virotherapy to 2037. Imugene's MD & CEO Leslie Chong emphasized the importance of these patent grants, highlighting the significance of China, Japan, and South Korea as major healthcare markets in Asia. The company's vision is to transform and improve cancer treatment, backed by a growing body of clinical evidence and peer-reviewed research. Imugene aims to be at the forefront of the rapidly growing global market for immuno-oncology therapies.